login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BIOMARIN PHARMACEUTICAL INC (BMRN) Stock News
USA
-
Nasdaq
- NASDAQ:BMRN -
US09061G1013
-
Common Stock
53.7
USD
-0.04 (-0.07%)
Last: 12/10/2025, 8:00:01 PM
53.64
USD
-0.06 (-0.11%)
Pre-Market:
12/11/2025, 8:45:11 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BMRN Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case
8 days ago - By: The Motley Fool
- Mentions:
STAA
INSM
PTCT
ACAD
...
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms
8 days ago - By: The Motley Fool
- Mentions:
PTCT
INSM
ACAD
FOLD
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?
8 days ago - By: Zacks Investment Research
- Mentions:
XENE
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
14 days ago - By: Zacks Investment Research
- Mentions:
ALKS
Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?
a month ago - By: Benzinga
- Mentions:
ELF
KRNT
ZBH
DUOL
This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
a month ago - By: BioMarin Pharmaceutical Inc.
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
a month ago - By: BioMarin Pharmaceutical Inc.
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
2 months ago - By: Benzinga
What to Expect from Biomarin Pharmaceutical's Earnings
2 months ago - By: Zacks Investment Research
- Mentions:
GILD
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
2 months ago - By: BioMarin Pharmaceutical Inc.
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
Please enable JavaScript to continue using this application.